Go to main content

Press Releases

Explore the archived press releases about AOP Health, its products, studies and cooperations. We will be happy to answer any questions or comments you may have via aop-health@aoporphan.com 

AOP Orphan Pharmaceuticals AG announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera

14. 3. 2017

AOP Orphan and PharmaEssentia announce pivotal phase III results for ropeginterferon alfa-2b in Polycythemia Vera

5. 12. 2016

AOP Orphan Pharmaceuticals AG announces European “approvable” opinion of its ultra-short acting beta blocker Rapibloc® (Landiolol)

11. 7. 2016

Roland Bindeus moves from Baxalta to AOP Health – new Head of the Hematology & Oncology Business Unit

4. 4. 2016

Suzie McFadzean – new Chief of Commercial Operations

13. 10. 2015

AOP Orphan strengthens core CNS specialty business with high promise in movement disorder treatments

19. 6. 2015